The insulin resistance-attenuating effect of LASSBio-2129 can be generated through daily glycemic control by inhibiting the DPP-4 enzyme, which is known to prolong the half-life of GLP-1 and GIP, thereby corroborating the effect observed in this study. This evidence concerns the gene GIP and Insulin resistance.